NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Recommendation of “Moderate Buy” from Brokerages

by · The Markets Daily

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twelve research firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, nine have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $49.00.

Several research firms recently commented on NAMS. Royal Bank Of Canada boosted their target price on NewAmsterdam Pharma from $47.00 to $51.00 and gave the stock an “outperform” rating in a research report on Tuesday. Truist Financial initiated coverage on NewAmsterdam Pharma in a report on Wednesday, March 18th. They issued a “buy” rating and a $57.00 price target on the stock. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Tuesday, April 21st.

View Our Latest Stock Analysis on NewAmsterdam Pharma

Insider Buying and Selling

In other news, CAO Louise Frederika Kooij sold 65,000 shares of the firm’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $35.69, for a total transaction of $2,319,850.00. Following the sale, the chief accounting officer owned 24,353 shares in the company, valued at approximately $869,158.57. This trade represents a 72.75% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 12.74% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of hedge funds have recently made changes to their positions in the business. Capital World Investors raised its holdings in NewAmsterdam Pharma by 17.1% in the 3rd quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock worth $279,358,000 after purchasing an additional 1,434,986 shares in the last quarter. Duquesne Family Office LLC lifted its holdings in shares of NewAmsterdam Pharma by 131.2% during the 3rd quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock valued at $54,710,000 after buying an additional 1,091,525 shares during the period. Castle Hook Partners LP purchased a new position in NewAmsterdam Pharma in the fourth quarter worth about $38,062,000. Adage Capital Partners GP L.L.C. boosted its position in NewAmsterdam Pharma by 54.5% in the second quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock worth $54,566,000 after purchasing an additional 1,062,359 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in shares of NewAmsterdam Pharma by 96.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,725,662 shares of the company’s stock valued at $60,536,000 after purchasing an additional 845,110 shares during the period. 89.89% of the stock is currently owned by institutional investors.

NewAmsterdam Pharma Stock Performance

Shares of NAMS stock opened at $34.83 on Monday. The firm’s 50 day moving average is $32.93 and its 200 day moving average is $33.09. The stock has a market capitalization of $4.07 billion, a P/E ratio of -19.46 and a beta of 0.08. NewAmsterdam Pharma has a 12 month low of $18.70 and a 12 month high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. The company had revenue of $3.04 million during the quarter. On average, equities analysts predict that NewAmsterdam Pharma will post -1.78 EPS for the current year.

About NewAmsterdam Pharma

(Get Free Report)

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.

See Also